Pfizer/Novartis Collaboration Brings Combined Strength To NASH Development
Combination therapy is expected to prevail in NASH. Pfizer and Novartis, while trailing smaller companies, are studying their candidates together in hopes of hitting on a winning combo for the multi-factorial disease.
You may also be interested in...
Novartis thinks tropifexor may prove to be best-in-class FXR agonist, while Pfizer notes the complementary activity of its ACC and DGAT2 inhibitors. Their NASH trial collaboration is heading toward a Phase II launch in 2020.
Deal for preclinical asset adds an anti-fibrotic mechanism to Novartis’ NASH program. Pliant produced preclinical data showing strong anti-fibrotic effect.
After multiple Phase IIb trial failures, Conatus says it will fulfill contractual obligations and consider strategic alternatives. Partner Novartis was already focused on other candidates and partnerships in NASH.